Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium
M.P. Mehta, P. Rodrigus, C.H. Terhaard, A. Rao, J. Suh, W. Roa, L. Souhami, A. Bezjak, M. Leibenhaut, R. Komaki, C.J. Schultz, R. Timmerman, T. Illidge, C.A. Meyers, W.J. Curran, S.C. Phan, J. Smith,Volume:
51
Year:
2001
Language:
english
Pages:
2
DOI:
10.1016/s0360-3016(01)02070-3
File:
PDF, 26 KB
english, 2001